Status
Recruiting
Phase
Phase 2
Enrollment
120
Locations
2
Results
Not posted
Publications
1
Study summary
The aim of this randomized controlled trial is to compare the efficacy and cost-effectiveness of using progestin with GnRH antagonist to prevent premature LH surge in poor responders undergoing double stimulation protocol.
Interventions
DRUG
HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.
DRUG
HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.
Timeline
First posted
Jan 18, 2024
Study start
May 8, 2024
Primary completion
Mar 1, 2027
Study completion
Aug 1, 2027
Results posted
Not reported
Registry updated
May 4, 2026
Outcomes
Medications costs per retrieved oocyte
Time frame · Ten to fifteen days after starting ovarian stimulation]
Total cost of medications used in all cycles/number of retrieved oocytes
Clinical pregnancy rate
Time frame · 5 weeks after embryo transfer]
Presence of intrauterine gestational sac detected by transvaginal ultrasound
Ongoing Pregnancy Rate
Time frame · 18 weeks after embryo transfer]
Pregnancies continued beyond 20 weeks gestation
Eligibility
Inclusion Criteria: Patients belonging to Poseidon group 4 Exclusion Criteria: * PCOS * Endometriosis * History of recurrent abortion
Study locations
Egypt. Showing up to 24 locations stored in the fast local snapshot.
Cairo University
Cairo, Cairo Governorate, Egypt
Bedaya Hospital
Giza, Egypt
Related trials
Ahmed Saad · Poor Ovarian Reserve · Infertility (IVF Patients)
Phase 1 / Phase 2
Not yet recruiting
100
2026-07
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Infertility
Phase 3
Recruiting
266
2026-07
ART Fertility Clinics LLC · Ovarian Stimulation
Not applicable
Recruiting
150
2026-06
Beni-Suef University · IVF · PCO
Phase 2 / Phase 3
Completed
200
2026-04
Assistance Publique - Hôpitaux de Paris · Infertility
Phase 4
Completed
129
2026-04
Institut Cancerologie de l'Ouest · Breast Cancer
Phase 2
Active, not recruiting
102
2026-03
Fundación Santiago Dexeus Font · Infertility
Phase 4
Recruiting
120
2026-03
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.